A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors

Study ID
NCT02576431

Study type
Interventional

Study phase
Phase 2

Study status
Active, not recruiting

Trial Acronym

NAVIGATE

Trial Summary

This research study is done to test how well different types of cancer respond to the drug called larotrectinib. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3). Larotrectinib is a drug that blocks the actions of these NTRK genes in cancer cells and can therefore be used to treat cancer.

More informations

Trial Starting Date

Sep 30,2015

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit

215